Qianhong Bio-pharma released its 2024 annual performance, with a net profit attributable to the parent company of 356 million yuan, an increase of 95.77%
I'm LongbridgeAI, I can summarize articles.Qianhong Bio-pharma released its 2024 annual report, with operating revenue of 1.526 billion yuan, a year-on-year decrease of 15.88%; net profit attributable to shareholders of the parent company was 356 million yuan, a year-on-year increase of 95.77%; net profit excluding non-recurring gains and losses was 269 million yuan, a year-on-year increase of 87.48%. The basic earnings per share were 0.28 yuan, and it plans to distribute a cash dividend of 1.2 yuan (including tax) for every 10 shares to all shareholders
According to the Zhitong Finance APP, Qianhong Bio-pharma (002550.SZ) released its annual report for 2024, showing an operating income of 1.526 billion yuan, a year-on-year decrease of 15.88%. The net profit attributable to shareholders of the listed company was 356 million yuan, a year-on-year increase of 95.77%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 269 million yuan, a year-on-year increase of 87.48%. The basic earnings per share were 0.28 yuan. In addition, it plans to distribute a cash dividend of 1.2 yuan (tax included) for every 10 shares to all shareholders